Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sirnagen Therapeutics Corporation focuses its patent portfolio on the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 2 pending office actions. These matters are being examined within 1 distinct art unit, suggesting a concentrated technical focus. Prosecution involves 2 distinct examiners.
GIBBS, TERRA C is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending action. Although the 2 pending office actions are within 1 distinct art unit, the involvement of 2 distinct examiners means that practitioners must account for different individual examination styles. The presence of 1 busiest examiner pending action under GIBBS, TERRA C indicates that the workload is divided among the examiners. This concentration in a single art unit within the Biotechnology & Pharmaceuticals field may allow for some consistency in the technical arguments used across the portfolio. Practitioners should monitor the specific requirements of the 2 distinct examiners to ensure that the 2 pending office actions are resolved efficiently.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261882 | COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT | YU, DAVID TUYANG | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18261882 | COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT | YU, DAVID TUYANG | 1635 | §103§112 | Non-Final OA | — | Pending | Jul 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSirnagen Therapeutics Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David Tuyang Yu has the most, with 1 of Sirnagen Therapeutics Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
